Markets

– Patients with axial spondyloarthritis (axSpA), who achieve sustained remission, benefit from continued CIMZIA® (certolizumab pegol) treatment either at the full or reduced maintenance dose, a post-hoc analysis of the C-OPTIMISE study confirms- Further information for healthcare providers considering certolizumab pegol treatment, if clinically needed, for their patients who are women of childbearing age, is being presented from one of the largest cohorts of prospective pregnancies with known outcomes in patients with axSpA, Crohn’s disease (CD), psoriatic arthritis (PsA), psoriasis (PSO) and rheumatoid arthritis (RA)- Long-term safety, efficacy and patient-reported outcomes and quality of life data on UCB’s investigational IL-17A and IL-17F inhibitor, bimekizumab, show its potential to make a meaningful difference for people living with ankylosing spondylitis (AS) and PsABRUSSELS, June 1, 2021 /PRNewswire/ — UCB, a global biopharmaceutical company, today announced that it will present new data for its Fc-free anti-TNF, CIMZIA® (certolizumab pegol), and its investigational IL-17A and IL-17F inhibitor, bimekizumab, at the European Congress of Rheumatology (EULAR) 2021 on June 2-5, 2021. A total of seven abstracts were accepted for this year’s E-Congress, all of which highlight UCB’s dedication to innovation in rheumatology and ongoing commitment to address unmet patient needs. Three of the seven abstracts will be

DANA POINT, Calif., May 31, 2021 /PRNewswire/ — Alter Health Group has announced that it will be changing their logo and brand styling across all of its entities, accompanied by an emotional and empowering commercial to be aired on television on Memorial Day, 2021.This transition to a new image is a push towards bringing substance abuse and mental health treatment out of the taboo shadows and into the modern era. Alter Health Group sees the attitude towards mental health shifting and choose to fully embrace the change, riding the wave with a full rebranding head to toe.The company will still be supporting the same health brands after the brand update, so existing clients have nothing to be concerned about. These supported groups include Dana Point Rehab Campus, California Rehab Campus, Alter Behavioral Health, Altignis Health and BeWellLine. Each location provides science-backed treatment methodologies that use the newest research data and technology giving patients the highest chance at success and reclaiming their lives as possible.Content from Alter Health Group’s new commercial is a gripping delivery of a life-changing opportunity. In just one minute, the team is able to showcase struggle, determination, courage and triumph all while igniting that same flame in every viewer

TORONTO, May 31, 2021 /CNW/ – Horizons ETFs Management (Canada) Inc. (“Horizons ETFs”) is announcing that the index methodology for the North American Psychedelics Index (the “Index”), is being changed effective June 7, 2021.The Index, which is owned and operated by Horizons ETFs and calculated by Solactive AG, is designed to provide a measure of the performance of North American publicly-listed life sciences companies focused on psychedelic medicines, and other companies with business activities in the psychedelics industry. The Index provides a diversified approach to the psychedelics industry, at weights that can easily and cost effectively be replicated, while at the same time reflecting the evolution of the industry in a timely fashion.The changes to the Index methodology are being made in order to enhance diversification, while improving the size and liquidity of the relevant selected constituents. A summary of the Index methodology changes are as follows:  An increase in the minimum Float Market-Capitalization requirement from CAD $25 million to CAD $40 million for new Index entrants with a decrease in minimum Float Market-Capitalization requirement for existing Index constituents from CAD $20 million to CAD $15 million;An increase in the minimum 3-Month Average Daily Traded Value from CAD $125,000 to CAD

BURNABY, British Columbia, May 31, 2021 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive management team will participate in the following investor conference:Jefferies 2021 Virtual Healthcare Conference on Wednesday, June 2, 2021 at 3:00 pm ET. The live webcast of the fireside chat can be accessed here.The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon’s website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event.About Xenon Pharmaceuticals Inc.We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contact:Maria McCleanXenon Pharmaceuticals Inc.Phone: 604.484.3353Email: investors@xenon-pharma.com

Jason Nadler is Chief Technology Officer (CTO) at EML Payments Limited (ASX: EML) (S&P/ASX 200). With a background in business and technology, he understands complex technical problems and solutions in the market. He translates this into how best it equates for the FinTech’s current and future customers. To enable accelerated growth through scalability, security, and automation, his team utilises the company’s global reach to provide reliable systems with innovative, market-leading strategies. In the following conversation, Jason reveals that ”we are a Microsoft shop.”

(RTTNews) – The Switzerland stock market opened lower Monday morning, and despite emerging into positive territory subsequently, faltered by noon and kept sliding as the day progressed to finally close weak. Amid a lack of significant positive triggers, investors chose to take some profits. The benchmark SMI, which hit a fresh high at 11,433.76, ended with a loss of 62.70 points or 0.55% at 11,363.45, the day’s low. Roche Holdings, Holcim, Novartis, Zurich Insurance Group, Swiss Re, UBS Group, Swiss Life Holding, Lonza Group and Credit Suisse shed 0.5 to 1%. Partners Group and Richemont, up 0.5% and 0.3%, respectively, were the two gainers in the SMI index. Among the stocks in the Swiss Mid Price Index, Dufry and Baloise Holding lost 1.4% and 1.1%, respectively. Tecan Group, Schindler Ps, Swiss Prime Site and Adecco ended lower by 0.7 to 0.85%. Flughafen Zurich gained nearly 1.5%, Lindt & Spruengli AG N climbed 1.3% and Lindt & Spruengli AG Part gained 1%. On the vaccination front, reports say the rate of vaccination against Covid-19 in Switzerland is now among the best in the world. The Swiss health ministry has reportedly said that a million doses of the Moderna vaccination arrived

OTTAWA, ON, May 31, 2021 /CNW/ – The Government of Canada is taking action to improve railway track safety to better protect those living and working near Canada’s rail corridors, while also ensuring that railway tracks are in optimal condition to safely move Canadian goods to market. Today, the Minister of Transport, the Honourable Omar Alghabra, announced that changes to the Rules Respecting Track Safety have been approved by Transport Canada. These changes are the result of a Ministerial Order that was issued in 2020 to address major risks that could cause derailments due to the condition of railway infrastructure. The Rules Respecting Track Safety specify safety requirements that railway companies must follow when inspecting and maintaining their railway track infrastructure. As a result of the new changes to the Rules, railway companies will be required to:put in place a certification process for employees who inspect tracks and supervise the restoration of tracks to make sure their personnel have the proper knowledge and experience to carry out their safety duties; establish a process to ensure that track maintenance and repair work meets regulatory requirements and the railway companies’ own standards to improve accountability; and develop and implement comprehensive plans to manage rail

TORONTO and BEIT SHEAN, Israel, May 31, 2021 /CNW/ – K.B. Recycling Industries Ltd., conducting business as Alkemy (“Alkemy” or, the “Company”), a leading environmental technology company based in Israel, announces the release of its consolidated financial statements for the interim period ended March 31, 2021 and related management discussion and analysis (“MD&A”). These documents, among others, will be posted on the Company’s website at www.alkemy.solutions and SEDAR at www.sedar.com.The Company also announces that its Annual and Special Meeting of shareholders (the “AGM”) will now be held on July 20, 2021 at 5:00 pm (IDT)/ 10:00 am (EDT).  As COVID-19 restrictions continue to affect several jurisdictions the AGM will be held through the TSX Trust virtual meeting platform.About K.B. Recycling Industries Ltd. K.B. Recycling Industries Ltd. is an environmental technology company based in Israel, and carries on business under the name “Alkemy”. Alkemy has developed a unique plastic recycling process to recycle plastic bags and sheets traditionally not considered economically viable for recycling and as such have become one of the largest plastic pollutants in the world. Alkemy employs a dynamic one-step process that does not require separate recycling and production plants. Alkemy’s process includes both recycling and finished product manufacturing

TAIPEI, May 31, 2021 /PRNewswire/ — Taer Innovation has won design awards including Good Design award from 2012 to 2014 Golden Pin Design award, Taiwan Excellence award in 2014 and Computex d&I award in 2014 for their products.The company focuses on medical innovation and technology. The company’s filtration masks consist of physical filtration, based on the nanoporous structure of the membrane (PTFE) as the barrier, infused with micro-current electric field filter (Bio-electric technology), along with biocompatible medical silicone. It protects wearers from airborne pathogens and is an essential safety device during the COVID-19 pandemic and in an environment with airborne health-threatening conditions. The mask features a snug yet comfortably fit, to protect against airborne pathogens. It comes in five sizes (XS, S, M, L, XL) and in two colors, black and transparent.Improved Safety and WearabilityThe filtration mask is made of medical-grade silicone, which is biocompatible and has good anti-allergic properties. It reduces allergies and “rubber” feelings and does not cause skin allergies, is easier to clean, and will not wear off. Our strategic partner, Nex-Si, committed to researching and developing the world’s only new technology, the Ion technology successfully developed the new plasma surface treatments for RTV silicone and electroplating products. With the application of biomedical materials, the plasma

Company announcement – No. 34 / 2021Total number of shares and voting rights in Zealand Pharma atMay 31, 2021Copenhagen, DK and Boston, MA,May 31, 2021– Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.  In Company announcement No. 31/2021 from May 20, 2021, Zealand announced an increase in share capital relating to the exercise of employee warrants. Following this announcement, the table below lists the total number of shares and voting rights in Zealand up to and including May 31, 2021.DateNumber of shares(nominal value of DKK 1 each)Share capital(nominal value in DKK)Number of voting rightsMay 31, 202143,451,84243,451,84243,451,842 # # #About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have